STOCK TITAN

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% functional cure rates. The presentation will focus on PBGENE-HBV, their gene editing approach targeting cccDNA elimination and HBV DNA inactivation. The company will present final preclinical safety data and phase 1 clinical trial plans following Clinical Trial Application approval in Moldova.

Precision BioSciences (Nasdaq: DTIL) ha annunciato un evento virtuale per investitori sulla Hepatite B, programmato per il 15 novembre 2024. L'evento presenterà Leader di Opinione e membri del Comitato Scientifico sulla Hepatite di Precision, che discuteranno l'attuale panorama dei trattamenti per l'epatite B, dove i tassi di cura funzionale raggiungono solo l'1-3%. La presentazione si concentrerà su PBGENE-HBV, il loro approccio di editing genetico mirato all'eliminazione del cccDNA e all'inattivazione dell'HBV DNA. L'azienda presenterà i dati finali sulla sicurezza preclinica e i piani per la sperimentazione clinica di fase 1, dopo l'approvazione della domanda di sperimentazione clinica in Moldova.

Precision BioSciences (Nasdaq: DTIL) anunció un evento virtual para inversores sobre la Hepatitis B, programado para el 15 de noviembre de 2024. El evento contará con Líderes de Opinión Clave y miembros del Consejo Asesor Científico de Hepatitis de Precision, que discutirán el panorama actual del tratamiento de la hepatitis B, donde las tasas de cura funcional alcanzan solo entre el 1-3%. La presentación se centrará en PBGENE-HBV, su enfoque de edición genética dirigido a la eliminación de cccDNA y la inactivación del ADN de HBV. La empresa presentará los datos finales de seguridad preclínica y planes para el ensayo clínico de fase 1 tras la aprobación de la Solicitud de Ensayo Clínico en Moldavia.

프리시전 바이오사이언스(나스닥: DTIL)는 2024년 11월 15일로 예정된 가상 헬리퍼스 B 투자자 이벤트를 발표했습니다. 이 이벤트에서는 프리시전의 간염 과학 자문 위원회 구성원들과 주요 의견 리더들이 현재의 간염 B 치료 환경에 대해 논의할 예정이며, 이 치료법의 기functional cura 비율은 1-3%에 불과합니다. 발표는 cccDNA 제거 및 HBV DNA 비활성화를 목표로 하는 그들의 유전자 편집 접근법인 PBGENE-HBV에 초점을 맞출 것입니다. 회사는 몰도바에서 임상 시험 신청 승인을 받은 후 최종 전임상 안전 데이터 및 1상 임상 시험 계획을 발표할 것입니다.

Precision BioSciences (Nasdaq: DTIL) a annoncé un événement virtuel pour les investisseurs sur l'hépatite B, prévu pour le 15 novembre 2024. L'événement mettra en vedette des leaders d'opinion clés et des membres du comité consultatif scientifique sur l'hépatite de Precision discutant du paysage actuel des traitements de l'hépatite B, où les taux de guérison fonctionnelle n'atteignent que 1 à 3 %. La présentation sera axée sur PBGENE-HBV, leur approche d'édition génétique visant l'élimination du cccDNA et l'inactivation de l'ADN du VHB. L'entreprise présentera les données finales de sécurité préclinique et les plans d'essai clinique de phase 1 après approbation de la demande d'essai clinique en Moldavie.

Precision BioSciences (Nasdaq: DTIL) gab bekannt, dass am 15. November 2024 ein virtuelles Investor-Event zur Hepatitis B stattfinden wird. Die Veranstaltung wird Schlüsselmeinungsführer und Mitglieder des wissenschaftlichen Beirats für Hepatitis von Precision präsentieren, die die aktuelle Behandlungslage der Hepatitis B erörtern, bei der nur eine funktionale Heilungsrate von 1-3% erreicht wird. Die Präsentation wird sich auf PBGENE-HBV, ihrem Ansatz zur Genbearbeitung mit dem Ziel der Eliminierung von cccDNA und der Inaktivierung von HBV-DNA, konzentrieren. Das Unternehmen wird die endgültigen präklinischen Sicherheitsdaten und die Pläne für klinische Prüfungen der Phase 1 nach Genehmigung des Antrags auf klinische Prüfung in Moldawien vorstellen.

Positive
  • Received Clinical Trial Application approval in Moldova for PBGENE-HBV
  • Additional global regulatory approvals are pending
  • Advancing to Phase 1 clinical trials with PBGENE-HBV
Negative
  • None.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting.

The event will feature Key Opinion Leaders in the field of Hepatitis and members of Precision’s Hepatitis Scientific Advisory Board, who will join to discuss their perspectives on the current unmet need and treatment landscape for chronic hepatitis B that unfortunately only results in 1-3% of patients achieving a functional cure. The discussion will include a deeper dive into the PBGENE-HBV gene editing approach that is uniquely designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV DNA. In addition, members of Precision BioSciences’ executive management team will highlight final PBGENE-HBV preclinical safety data and phase 1 clinical trial plans now that Precision has received Clinical Trial Application approval in Moldova with other global regulatory approvals pending.

Investor Event Webcast Presentation and Registration Information

The event will be webcasted live on Friday, November 15, 2024, at 10:00 am EST (7:00 a.m. PST). To access the presentation and webcast, please use the following link or go to Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcast will be available following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into a gene to cause expression/add function), elimination (removing a genome, e.g., viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our product candidates (including PBGENE-HBV); the unique design of PBGENE-HBV to directly eliminate cccDNA and inactivate integrated HBV DNA with high specificity, potentially leading to functional cures or providing a better chance of functional cures; the expected timing of regulatory processes (including filings such as IND’s and CTA’s and studies for PBGENE-HBV and the acceptance of these filings by regulatory agencies), the suitability of PBGENE-HBV for the treatment of hepatitis and the targeting of the root cause of the disease, expectations about operational initiatives, strategies, and further development of PBGENE-HBV; expectations about achievement of key milestones; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “design”, “designed,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “strive,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators’ or other licensees’ ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators’ or other licensees’ development of product candidates; our or our collaborators’ or other licensees’ ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators’ and other licensees’ ability to enroll patients; changes in interim “top-line” and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees’ ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators’ or other licensees’ ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences (DTIL) host its Hepatitis B Investor Event?

Precision BioSciences will host its Hepatitis B Investor Event on November 15, 2024, from 7:00 a.m. to 8:30 a.m. PST.

What is the current functional cure rate for chronic hepatitis B treatments discussed in DTIL's presentation?

According to the presentation, current hepatitis B treatments only result in 1-3% of patients achieving a functional cure.

Where has DTIL received Clinical Trial Application approval for PBGENE-HBV?

Precision BioSciences has received Clinical Trial Application approval in Moldova for PBGENE-HBV.

What is the mechanism of action for DTIL's PBGENE-HBV treatment?

PBGENE-HBV is designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV DNA.

Precision BioSciences, Inc.

NASDAQ:DTIL

DTIL Rankings

DTIL Latest News

DTIL Stock Data

65.10M
7.23M
6.78%
45.15%
2.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM